FDA Biologics Center Performance To Be Reviewed By Advisory Committees
This article was originally published in The Pink Sheet Daily
Center for Biologics Evaluation & Research expects the review to take place within the year. CDER Office of Drug Evaluation VI's continued use of CBER facilities will likely be part of that review.
You may also be interested in...
The agency is understood to be finalizing a plan that would complete the integration of the oncology review teams as originally intended under the CDER/CBER consolidation. Oncology Drug Products Division Director Richard Pazdur, MD, and ODE VI Director Karen Weiss, MD, are potential candidates to head the merged cancer office.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles